QI
QIA.F QIAGEN NV
- Market cap
- EUR 9.36B
- P/E
- 28.5x
- P/B
- 2.99x
- ROE
- 10.6%
- Dividend yield
- 0.69%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QIA.F undervalued?
Graham numberQIA.F trades 94.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
QIAGEN NV fundamental analysis
No fundamental analysis for QIAGEN NV yet.
QIAGEN NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About QIAGEN NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components fo…
Full company profileQIAGEN NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
QIAGEN NV annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.34B | 1.42B | 1.50B | 1.53B | 1.87B | 2.25B | 2.14B | 1.97B | 1.98B | 2.09B | 2.10B |
| Gross Profit | 845M | 923M | 1.00B | 1.01B | 1.23B | 1.45B | 1.38B | 1.23B | 967M | 1.30B | 1.34B |
| Operating Income | 98.8M | 153M | 267M | 314M | 537M | 658M | 578M | 445M | 200M | 520M | 545M |
| EBITDA | - | 381M | 499M | 228M | 716M | 895M | 779M | 689M | 368M | 717M | 716M |
| Net Income | 80.4M | 40.4M | 190M | -41.5M | 359M | 513M | 576M | 341M | 83.6M | 425M | 369M |
| EPS | - | 0.18 | 0.84 | -0.18 | 1.58 | 2.26 | 2.53 | 1.54 | 0.39 | 2.06 | 1.79 |
| Balance Sheet | |||||||||||
| Total Assets | 4.31B | 5.04B | 5.75B | 5.24B | 5.91B | 6.15B | 6.35B | 6.12B | 5.69B | 6.28B | 5.94B |
| Total Liabilities | 1.70B | 2.50B | 3.11B | 2.70B | 3.11B | 3.05B | 2.96B | 2.31B | 2.12B | 2.50B | 2.47B |
| Shareholders' Equity | 2.61B | 2.54B | 2.63B | 2.54B | 2.80B | 3.10B | 3.39B | 3.81B | 3.57B | 3.78B | 3.47B |
| Cash & Short-term Investments | 439M | 658M | 1.16B | 624M | 598M | 881M | 730M | 668M | 664M | 839M | 805M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 342M | 287M | 359M | 331M | 458M | 676M | 751M | 432M | 674M | 654M | 596M |
| Capital Expenditure | 93.9M | 90.1M | 110M | 118M | 133M | 139M | 56.3M | 157M | 171M | 207M | 176M |
| Free Cash Flow | - | 162M | 209M | 56.0M | 154M | 432M | 593M | 275M | 502M | 447M | 420M |
| Ratios | |||||||||||
| ROE | 3.1% | 1.6% | 7.2% | -1.6% | 12.8% | 16.6% | 17.0% | 9.0% | 2.3% | 11.2% | 10.6% |
| ROA | 1.9% | 0.8% | 3.3% | -0.8% | 6.1% | 8.3% | 9.1% | 5.6% | 1.5% | 6.8% | 6.2% |
| Net Profit Margin | 6.0% | 2.8% | 12.7% | -2.7% | 19.2% | 22.8% | 26.9% | 17.4% | 4.2% | 20.3% | 17.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
QIAGEN NV dividends
- Dividend yield
- 0.69%
- Forward dividend
- 0.31 EUR
- Payout ratio
- 12.8%
- Ex-dividend date
- Jul 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 54.2M | 0.26 | 12.8% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 19:20 on Jan 8, 2026.
Who owns QIAGEN NV
- Insiders 0.48%
- Institutions 76.90%
- Public & others 22.62%
- Shares outstanding 206M
- Free float 205M
QIAGEN NV company profile
- Company name
- QIAGEN NV
- Ticker
- QIA.F
- ISIN
- NL0015002CX3
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5,400
- Fiscal year end
- December
- Address
- Hulsterweg 82, Venlo, Netherlands, 5912 PL
- Phone
- 31 77 355 6600
- Website
- qiagen.com
About QIAGEN NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
QIAGEN NV management
10- Dr. Roland SackersCFO, MD & Member of Management Board · born 1968
- Mr. Jonathan M. PrattCEO & Member of Management Board · born 1970
- Mr. Antonio SantosSenior VP & Head of Global Operations
- Mr. Daniel Wendorff CEFA, CIIAVP & Head of Investor Relations
- Mr. John GilardiVP & Head of Corporate Communications
- Ms. Stephany FosterSenior VP & Head of Human Resources · born 1979
- Dr. Thomas SchweinsSenior Vice President of Life Science Business Area
- Dr. Thomas TheuringerSenior Director & Head of External Communications
- Mr. Jean-Pascal ViolaSenior VP & Head of Corporate Strategy and Business Development
- Mr. Nitin SoodSenior VP & Head of Product Portfolio & Innovation · born 1973